In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


This content is currently on FREE ACCESS, enjoy another 54 days of free consultation

In these unprecedented times, the ESC is doing everything it can to support its community: FREE access to all ESC 365 content until 31 July: explore more than 125,000 educational resources.

From 1 August onwards, support our mission by becoming a member.

Assessment of treatment with Carvedilol in preventing early stage left ventricular dysfunction in breast cancer patients by 2D speckle tracking echocardiography.

Session Poster session 1

Speaker Maryam Moshkani Farahani

Event : EuroEcho 2018

  • Topic : imaging
  • Sub-topic : Tissue Doppler, Speckle Tracking and Strain Imaging
  • Session type : Poster Session

Authors : M Moshkani Farahani (Tehran,IR), S Nourian (Tehran,IR)

Authors:
M Moshkani Farahani1 , S Nourian1 , 1Baqiyatallah Medical Sciences University - Tehran - Iran (Islamic Republic of) ,

Citation:
European Heart Journal - Cardiovascular Imaging ( 2019 ) 20 ( Supplement 1 ), i192

Background/Introduction: Treatment-induced cardiotoxicity (TIC) is one of major side effects of trastuzumab treatment in breast cancer patients. Left ventricular (LV) dysfunction is the leading cause of TIC. Development of TIC during cancer treatment may force patients to modifications or withdrawing the treatment.
Purpose: In this trial we evaluated the prophylactic effect of carvedilol on LV dysfunction in breast cancer patients receiving trastuzumab using 2D speckle tracking echocardiography (2DSTE).
Methods: We conducted open label randomized clinical trial (RCT) and enrolled 71 non-metastatic HER-2 positive breast cancer patients whom were candidate to receive trastuzumab. Carvedilol was administered concomitantly with trastuzumab standard regimen with dosage of 6.25 mg twice a day and up titrated to maximum tolerated dosage. Speckle tracking echocardiography parameters to evaluate left ventricular systolic and diastolic function were evaluated initially and 3 months thereafter. Results: Thirty six patients were randomly assigned to carvedilol group and 35 patients to control group. Mean LV ejection fraction (LVEF) didn’t significantly different in both groups either between two groups (p=.61) during follow-up. In contrast, global longitudinal strain of LV (GLS) (p=.000) and strain rate of LV systolic function (SRS) (p=.004)-as marker of LV systolic function- were reduced in control group. Furthermore, LV strain rate of early (SRE) and late (SRA) diastolic function were preserved in patients received prophylactic carvedilol, p=.000 and p=.005 respectively.
Conclusion: concomitant carvedilol treatment with maximum tolerable dose in patients with nonmetastatic HER2 positive breast cancer under treatment trastuzumab might be effective on reduction of systolic and diastolic echocardiography findings other than LVEF in patients with weak markers of heart failure.

This content is currently on FREE ACCESS, enjoy another 54 days of free consultation

In these unprecedented times, the ESC is doing everything it can to support its community: FREE access to all ESC 365 content until 31 July: explore more than 125,000 educational resources.

From 1 August onwards, support our mission by becoming a member.



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are